Partner 7: TARTU ÜLIKOOL - University Of Tartu (UTARTU)
University of Tartu is an academic institution with main focus on under- and postgraduate teaching and research. The Department of Chemistry of the University has a well equipped and fully accredited laboratory for the measurement of drug concentrations in body fluids including methodology to measure meropenem concentrations in blood sera and CSF. Previous meropenem PK studies have dealt with tissue PK assessed by microdialysis in adults. Tartu University Clinics is a multidisciplinary hospital with 986 beds covering the population of 500,000 and 5,000 annual births. The other institution involved is Tallinn Children’s hospital that for neonatal cases covers an area with the population of 800,000 with 10,000 births per year. The population PK analysis will be conducted at the University of Uppsala.
At the Institute of Microbiology of the University of Tartu we have formed a research group to evaluate the pathomechanisms and management of infections in neonatal age. The group very much research oriented consists of neonatologists, microbiologists, clinical pharmacologist and chemists. The leader of the group is Irja Lutsar who has experience in the pharmacokinetic studies in children and experimental animals as well as in designing and conducting international clinical trials. The main aims of the group are to evaluate antibiotic pharmacokinetics and pharmacodynamics, especially in extremely low birth weight infants and look how antibiotics interfere with the normal bowel colonisation. Our most recent studies include evaluation of pharmacokinetics of penicillin G in extremely low birth weight infants and a recently completed cluster randomised trial comparing efficacy of penicillin G and ampicillin both combined with gentamicin in the empiric therapy of early onset neonatal sepsis.
Population PK group at Uppsala University led by prof. Mats Karlson consist of 40 people, 15 of which have PhDs, in the pharmacometrics group with a strong international presence. Pharmacometric research focuses on nonlinear mixed effects (”population”) models. Research at the pharmacometrics group can be divided into four main areas. First, development and evaluation of methods for efficient and robust model building. This involves development of estimation algorithms, methods for model diagnosis and sequential procedures for model building. The result of the research, when applicable, is made available as free software. Secondly, so-called platform models are being developed for the use in specific therapeutic areas or for particular therapeutic/pharmacological principles. Such a model may involve the time-course a system biomarker or a set of such biomarkers during normal, diseased or provoked situations. The third research area concerns utilization of the developed models for the purpose of designing studies, deciding upon dosing strategies and other developmental decisions. Last, we also do analyses of dose-concentration-response data from trials to understand therapies with existing drugs with the aim of allowing improved therapy. The facility has all necessary equipment for performing pharmacometric analysis, including a powerful computer cluster, software licences and in-house developed software. UTARTU NICU has an estimated number of about 50 late onset Sepsis per year and about 5 cases of neonatal meningitis.
At the Institute of Microbiology of the University of Tartu we have formed a research group to evaluate the pathomechanisms and management of infections in neonatal age. The group very much research oriented consists of neonatologists, microbiologists, clinical pharmacologist and chemists. The leader of the group is Irja Lutsar who has experience in the pharmacokinetic studies in children and experimental animals as well as in designing and conducting international clinical trials. The main aims of the group are to evaluate antibiotic pharmacokinetics and pharmacodynamics, especially in extremely low birth weight infants and look how antibiotics interfere with the normal bowel colonisation. Our most recent studies include evaluation of pharmacokinetics of penicillin G in extremely low birth weight infants and a recently completed cluster randomised trial comparing efficacy of penicillin G and ampicillin both combined with gentamicin in the empiric therapy of early onset neonatal sepsis.
Population PK group at Uppsala University led by prof. Mats Karlson consist of 40 people, 15 of which have PhDs, in the pharmacometrics group with a strong international presence. Pharmacometric research focuses on nonlinear mixed effects (”population”) models. Research at the pharmacometrics group can be divided into four main areas. First, development and evaluation of methods for efficient and robust model building. This involves development of estimation algorithms, methods for model diagnosis and sequential procedures for model building. The result of the research, when applicable, is made available as free software. Secondly, so-called platform models are being developed for the use in specific therapeutic areas or for particular therapeutic/pharmacological principles. Such a model may involve the time-course a system biomarker or a set of such biomarkers during normal, diseased or provoked situations. The third research area concerns utilization of the developed models for the purpose of designing studies, deciding upon dosing strategies and other developmental decisions. Last, we also do analyses of dose-concentration-response data from trials to understand therapies with existing drugs with the aim of allowing improved therapy. The facility has all necessary equipment for performing pharmacometric analysis, including a powerful computer cluster, software licences and in-house developed software. UTARTU NICU has an estimated number of about 50 late onset Sepsis per year and about 5 cases of neonatal meningitis.